The coagulation factor XI (FXI) from the liver acts as an endocrine molecule in the heart, protecting it from heart failure. Scientists at the University of California, Los Angeles (UCLA) found that ...

Do patients with renal disease have inherent coagulopathy? What prothrombin time (PT)/partial thromboplastin time (PTT) values can be expected with end-stage renal disease (ESRD)? —OMEL FIGUEROA, PA-C ...

The impact of the characteristics of extrahepatic organ failure (EHOF) including the onset time, number, type, and sequence on the prognosis of acute-on-chronic liver failure (ACLF) patients remains ...

Chronic liver disease disrupts the delicate balance of the coagulation system by impairing synthesis of both pro- and anti-coagulant factors. As liver fibrosis advances, production of clotting factors ...

AUC, area under the curve; cALSS, centrifugation artificial liver support systems; MA, maximum amplitude; R, reaction time; ROC, receiver operating characteristic curve. In this prospective single-arm ...

Anticoagulants are one of the most commonly prescribed medication classes, and the utilization of these agents is on the rise. Anticoagulants are prescribed for many indications, including prevention ...

Drug resistance is defined as the lack of expected response to a standard therapeutic dose of a drug or as resistance resulting from biologic changes in the target, as occurs in antibiotic resistance.

The treatment of choice for proximal venous thrombosis is anticoagulation. In situations where anticoagulation is absolutely contraindicated or when anticoagulation has failed in the face of an acute ...

Combination of bevacizumab (B) plus immunotherapy, with interleukin-2 (IL-2) and interferon-α (IFN-α) plus chemotherapy (BIC) in patients with metastatic renal cell cancer (mRCC): Dose-finding phase ...